168
Participants
Start Date
April 29, 2024
Primary Completion Date
April 11, 2025
Study Completion Date
August 22, 2025
Enobosarm
Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
Semaglutide
Semaglutide for Chronic Weight Management
Centennial Medical Group (CMG), Elkridge
Universal Axom Clinical Research, Doral
Altus Research, Lake Worth
Cullman Clinical Trials, Cullman
Pinnacle Trials, Anniston
SKY Integrative Medical Center, Ridgeland
MARC Research Center, Louisville
Lillestol Research LLC, Fargo
Clinvest Headlands LLC, Springfield
DelRicht Research - New Orleans, New Orleans
Pennington Biomedical, Baton Rouge
Clinical Trials of Texas, LLC DBA Flourish Research, San Antonio
Palm Research Center, Las Vegas
Artemis Institute for Clinical Research, San Diego
Veru Inc.
INDUSTRY